Across a twelve-month window, four programs reached their inflection points: GNX1021 cleared by Japan PMDA, GNX201-ADC co-development with Nippon Kayaku signed, SPD8 Phase 3 topline due Q2, and our second biosimilar program initiated. GlycoNex is actively partnering across the pipeline.
Each below is a structural BD signal, not a marketing claim — patents granted, regulatory clearances, manufacturing capacity, and a research lineage extending back to the founding of TACA biology.
GlycoNex was founded as a collaboration with the late Dr. Sen-itiroh Hakomori, whose laboratory established much of the modern foundation of tumor-associated carbohydrate antigen biology. The GlycoSH antibody bank has been accumulated continuously since the company's founding — a depth of starting material that cannot be matched on a short timescale.
In April 2026, Japan's Pharmaceuticals and Medical Devices Agency cleared lead glycan-targeted ADC GNX1021 for first-in-human Phase 1 in gastrointestinal cancers. This is the first regulatory validation of the company's glycan-directed ADC approach — a discrete, externally-verifiable proof point that pipeline maturity has reached the clinic.
Vertical integration from discovery through clinical supply. The 50L and 200L bioreactor production scales at our New Taipei facility support GlycoNex's own Phase 1 programs and are operated externally as CDMO services — partners do not depend on a third party for clinical material, and timelines are not exposed to external slot allocation.
More than forty patents granted across nine jurisdictions, with pending filings in seven more. The portfolio spans antibodies, ADC compositions, manufacturing methods, and biosimilar process patents — a structural signal that the company has invested in the IP scaffolding licensees and co-development partners require.
GlycoNex is in active partnering discussions across the pipeline. Over the past twelve months, the company has executed more than twenty confidentiality and non-disclosure agreements with global pharma and biotech counterparties, with multiple discussions ongoing at various stages of evaluation. Our BD team maintains a continuous physical presence at six international conferences each year, where we hold tailored asset-by-asset partnering meetings.
GlycoNex BD maintains a consistent presence at the following events. Reach out before each to request a meeting.
Each card below is a deal-sheet view; scientific detail lives on the Pipeline and Technology pages. Programs not listed here are not currently open for partnership.
GNX1021 is GlycoNex's lead glycan-targeted antibody-drug conjugate against branched Lewis B/Y, cleared by Japan PMDA for first-in-human Phase 1 in April 2026. It is available for either global out-licensing or co-development; GlycoNex is equally interested in licensing structures that preserve mutual long-term value. The PMDA clearance defines the partnering window — engaging before Phase 1 data lands is when the economics are most favourable to a development partner.
GNX201-ADC pairs antibody-lock technology in-licensed from Precisemab — held dormant in circulation and selectively activated in the tumor microenvironment — with a glycan-targeted antibody-drug conjugate construct. In March 2026, we signed a preclinical co-development agreement with Nippon Kayaku, who contribute clinical trial strategy and operational expertise. GNX201-ADC is available for licensing as a discrete product; additional partnership opportunities remain available — please contact BD to discuss scope.
SPD8 is a denosumab biosimilar in pivotal Phase 3 for osteoporosis, with topline data due Q2 2026. Japanese commercialization rights were licensed to a Japanese pharmaceutical partner in December 2024 under an agreement structured around upfront and milestone payments based on development and commercial progress — a proof of execution, not a constraint elsewhere. Ex-Japan territories are open now.
The GlycoSH antibody bank is GlycoNex's proprietary collection of monoclonal antibodies targeting tumor-associated carbohydrate antigens, accumulated continuously since 2001. For external partners, the engagement model is collaboration screening: we work jointly with a partner against a defined target or indication, accessing the bank under a structured collaboration agreement. There is no library subscription, marketplace, or self-service portal.
In 2013, Otsuka Pharmaceutical took a 5% equity position in GlycoNex following the 2009 GNX8 out-licensing agreement. That stake is still held today — a thirteen-year relationship spanning the regulatory clearance of our lead ADC, the build-out of in-house GMP-compliant manufacturing, and the maturation of the GlycoSH antibody bank. We do not characterize Otsuka as a current development partner — we point instead to the duration of the shareholder relationship. A globally-recognized Japanese pharmaceutical company has maintained its 5% equity stake in GlycoNex across three pipeline generations.
A non-exhaustive view of recent ADC out-licensing deals across the industry. These transactions illustrate that the partnering market for antibody-drug conjugates is active at multiple development stages. We list these for context only — GlycoNex does not draw direct comparisons to its own assets.
Email mail@glyconex.com.tw with a brief description of your company, area of interest, and the asset or capability you would like to discuss. Use subject line "Partnering Inquiry" so the message routes to BD on receipt.
We sign a mutual confidentiality agreement using either party's standard form, and follow up within five business days with a non-confidential overview deck scoped to your area of interest. From there we schedule a working call with the BD lead and the asset's program lead.
Tailored data-room access under NDA — clinical, CMC, and IP packages structured to the partnership model under discussion. From the data room, term-sheet conversations follow as appropriate to the asset and counterparty.
Initial replies as quickly as scheduling allows; please mention any time-sensitive context (e.g. a specific conference window) in your message.
GlycoNex BD maintains a continuous presence at six international conferences each year. Request a meeting in advance by emailing the address at left.
GlycoNex is actively seeking global licensing and co-development partners across GNX1021, GNX201-ADC, ex-Japan SPD8 rights, and GlycoSH collaboration screening.
Start a Conversation →